Schoch Charles 4
4 · Candel Therapeutics, Inc. · Filed Jan 28, 2026
Research Summary
AI-generated summary of this filing
Candel (CADL) CFO Charles Schoch Receives 232,000-Share Award
What Happened
- Charles Schoch, Chief Financial Officer of Candel Therapeutics (CADL), received a derivative award on January 26, 2026 to acquire 232,000 shares. The Form 4 lists the acquisition price as $0.00 (derivative award/option), indicating a compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-01-26; Form 4 filed: 2026-01-28 (appears timely).
- Transaction type: Award/Grant (derivative). Amount: 232,000 underlying shares; price reported $0.00.
- Shares owned following the transaction: not specified in the provided filing.
- Footnote: the option is subject to time-based vesting — vests and becomes exercisable in 48 equal monthly installments beginning January 26, 2026, contingent on continued service.
Context
- This was a compensation award (an option-style derivative), not a cash purchase or sale. The award vests over four years, so only a portion will become exercisable each month if Schoch remains employed. Such grants are common executive compensation and do not represent an immediate market buy signal.
Insider Transaction Report
Form 4
Schoch Charles
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-01-26+232,000→ 232,000 totalExercise: $6.01Exp: 2036-01-26→ Common Stock (232,000 underlying)
Footnotes (1)
- [F1]This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date.
Signature
/s/ Charles Schoch|2026-01-28